Foamix (FOMX) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019 4:23 PM EDTFDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date
Conference Call Scheduled for Wednesday May 8th at 8:30am Eastern Time
REHOVOT, Israel and BRIDGEWATER, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (Foamix Pharmaceuticals or the Company), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced financial results for the first quarter ended March 31, 2019 and provided a corporate update.
Foamix has achieved a number of important... More
